[ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2017, Volume : 10, Issue : 9
First page : ( 3043) Last page : ( 3048)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2017.00540.6

Formulation and Evaluation of Irbesartan nanosuspension for Dissolution Enhancement

Khushboo Mistry, Naik Kavya,  Vasanthi, Menezes Alicia, Naha Anup*, Koteshwara K.B., Pai K. Girish

Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka-576104, India

*Corresponding Author E-mail: anup.naha@manipal.edu

Online published on 16 May, 2018.


Irbesartan, an angiotensin receptor blocker, a BCS class II drug is effective in lowering blood pressure but is having low aqueous solubility and low bioavailability. Hence, the present study was aimed to prepare and evaluate nanosuspension of Irbesartan for enhancement of dissolution. Preformulation studies like, DSC, FTIR was performed to evaluate the drug excipient compatibility. A full factorial method was utilized to study the effect of various factors such as surfactant concentration, sonication amplitude and sonication time on Irbesartan nanosuspension in two levels using Design Expert 10 software. In vitro drug release of optimized and pure drug was performed in pH 1.2 and pH 6.8 buffers. FT-IR and DSC studies showed no interaction between the drug and the excipients. Optimized nanosuspension showed particle size (149.639 nm), PDI (0.195) and zeta potential (−5.639). The nanoparticle formulation showed a prolonged improved drug release for 24 hours in phosphate buffer pH 6.8 (89.09%) as compared to pure drug dispersion (67.69%)



Nanosuspension, Irbesartan, Solubility, Design of experiment, Dissolution.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
722,676,206 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.